Paper
Assessing the efficacy and safety of rivaroxaban as a warfarin alternative in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy: A randomized clinical trial.
Published Oct 1, 2022 · Saghar Barati, Hossein Amini, Z. Ahmadi
Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
6
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
RCT
Study Snapshot
Rivaroxaban may be as effective as warfarin in treating chronic thromboembolic pulmonary hypertension after endarterectomy in the short term, but long-term follow-up studies are needed to confirm this treatment strategy.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Full text analysis coming soon...
References
—
···
—
···
—
···
—
···
—
···
—
···
—
···
—
···
Citations
—
···
—
···
—
···
—
···
—
···
—
···
—
···
—
···